Capital Group Investment Management PTE. LTD. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Capital Group Investment Management PTE. LTD. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,867 shares of the biopharmaceutical company’s stock after selling 3,089 shares during the period. Capital Group Investment Management PTE. LTD.’s holdings in Regeneron Pharmaceuticals were worth $2,213,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Los Angeles Capital Management LLC raised its stake in Regeneron Pharmaceuticals by 5.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 100,508 shares of the biopharmaceutical company’s stock worth $77,579,000 after purchasing an additional 5,173 shares during the period. Havemeyer Place LP purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $330,000. Ramirez Asset Management Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $39,000. Greykasell Wealth Strategies Inc. raised its stake in Regeneron Pharmaceuticals by 31.0% during the fourth quarter. Greykasell Wealth Strategies Inc. now owns 478 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 113 shares during the period. Finally, MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $635.45 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $67.18 billion, a PE ratio of 15.48, a P/E/G ratio of 1.40 and a beta of 0.25. Regeneron Pharmaceuticals, Inc. has a 12-month low of $485.00 and a 12-month high of $821.11. The business’s fifty day moving average price is $706.93 and its 200 day moving average price is $742.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $8.22 EPS. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on REGN. Morgan Stanley lifted their target price on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. BMO Capital Markets lowered their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Leerink Partners reiterated a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research report on Monday, May 18th. Finally, Canaccord Genuity Group reduced their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron expanded its cancer therapy partnership with CytomX Therapeutics, a deal that could generate up to $4 billion in potential milestones and broadens its bispecific oncology pipeline. REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
• Positive Sentiment: The company also reported highly favorable Lynozyfic trial results in light chain amyloidosis, which supports the view that Regeneron’s clinical pipeline may have additional upside. A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
• Positive Sentiment: Regeneron said it will highlight new data from its metabolic disease, ophthalmology and rare disease programs at upcoming ADA and ENDO meetings, giving investors another near-term catalyst to watch. Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO
• Neutral Sentiment: Parabilis Medicines, a Regeneron-partnered biotech, is pursuing an IPO to advance zolucatetide into Phase III, which could indirectly reflect on Regeneron’s partner network but does not directly change REGN’s fundamentals. Parabilis eyes $475m IPO to push lead asset into Phase III
• Negative Sentiment: An investor alert from Pomerantz LLP announced an investigation into claims on behalf of Regeneron shareholders, which may create some legal overhang and weigh on sentiment. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. – REGN

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.